| Literature DB >> 26985312 |
Jonathan E Wilson1, Ravi Kurukulasuriya1, Mikhail Reibarkh1, Maud Reiter1, Aaron Zwicker1, Kake Zhao1, Fengqi Zhang1, Rajan Anand1, Vincent J Colandrea1, Anne-Marie Cumiskey2, Alejandro Crespo1, Ruth A Duffy2, Beth Ann Murphy2, Kaushik Mitra2, Douglas G Johns2, Joseph L Duffy1, Petr Vachal1.
Abstract
Using the collective body of known (CETP) inhibitors as inspiration for design, a structurally novel series of tetrahydroquinoxaline CETP inhibitors were discovered. An exemplar from this series, compound 5, displayed potent in vitro CETP inhibition and was efficacious in a transgenic cynomologus-CETP mouse HDL PD (pharmacodynamic) assay. However, an undesirable metabolic profile and chemical instability hampered further development of the series. A three-dimensional structure of tetrahydroquinoxaline inhibitor 6 was proposed from (1)H NMR structural studies, and this model was then used in silico for the design of a new class of compounds based upon an indoline scaffold. This work resulted in the discovery of compound 7, which displayed potent in vitro CETP inhibition, a favorable PK-PD profile relative to tetrahydroquinoxaline 5, and dose-dependent efficacy in the transgenic cynomologus-CETP mouse HDL PD assay.Entities:
Keywords: CETP inhibition; HDL; cholesterol ester transfer protein; indoline; tetrahydroquinoxaline
Year: 2016 PMID: 26985312 PMCID: PMC4789658 DOI: 10.1021/acsmedchemlett.5b00404
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345